Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score® Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemother

Independently Led by ECOG-ACRIN Research Group, TAILORx Prospective, Randomized Phase III Clinical Trial Results to be Presented Today in the Plenary Session at ASCO Annual Meeting TAILORx-defined Cutoff for Definitively Determining Chemotherapy Benefit with Oncotype DX® Usher in a New...

from PR Newswire: //https://ift.tt/2kIHZqJ